OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing OPK88004, an androgen receptor modulator for benign prostate hypertrophy and other urologic and metabolic conditions; OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity; hGH-CTP, a growth hormone injection that is in Phase III clinical trials; and Factor VIIa drug for hemophilia. In addition, it develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, marketing, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:OPK
CUSIP68375N10
Phone305-575-4100
Debt
Debt-to-Equity Ratio0.03
Current Ratio1.10
Quick Ratio0.94
Price-To-Earnings
Trailing P/E Ratio-20.31
Forward P/E Ratio-21.81
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.07 billion
Price / Sales3.09
Cash FlowN/A
Price / CashN/A
Book Value$3.37 per share
Price / Book1.75
Profitability
EPS (Most Recent Fiscal Year)($0.29)
Net Income$-308,870,000.00
Net Margins-31.27%
Return on Equity-8.76%
Return on Assets-6.50%
Miscellaneous
Employees6,030
Outstanding Shares559,470,000
Market Cap$3,334.46
OPKO Health (NASDAQ:OPK) Frequently Asked Questions
What is OPKO Health's stock symbol?
OPKO Health trades on the NASDAQ under the ticker symbol "OPK."
How were OPKO Health's earnings last quarter?
OPKO Health (NASDAQ:OPK) issued its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05. The biotechnology company earned $254.90 million during the quarter, compared to analysts' expectations of $236.90 million. OPKO Health had a negative return on equity of 8.76% and a negative net margin of 31.27%. The firm's quarterly revenue was down 4.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.06) EPS. View OPKO Health's Earnings History.
When is OPKO Health's next earnings date?
What price target have analysts set for OPK?
5 Wall Street analysts have issued 12-month target prices for OPKO Health's stock. Their forecasts range from $6.50 to $20.00. On average, they expect OPKO Health's share price to reach $11.30 in the next twelve months. This suggests a possible upside of 91.9% from the stock's current price. View Analyst Ratings for OPKO Health.
What is the consensus analysts' recommendation for OPKO Health?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OPKO Health in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
What are Wall Street analysts saying about OPKO Health stock?
Here are some recent quotes from research analysts about OPKO Health stock:
- 1. According to Zacks Investment Research, "OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. " (5/25/2018)
- 2. Barrington Research analysts commented, "We are maintaining our OUTPERFORM investment rating on OPK shares and our price target remains $7. We arrive at our price target via a DCF methodology for its current commercial business plus the hGH-CTP program. We assign an additional $1 of value for the rest of OPKO’s product pipeline." (5/9/2018)
- 3. Cantor Fitzgerald analysts commented, "Positives from the quarter that support our thesis: 1) On 01/12/18 OPK announces that GeneDx, Inc., a subsidiary of OPKO’s BioReference Laboratories, has entered into a research collaboration with the Nijmegen, Netherlands." (5/8/2018)
Are investors shorting OPKO Health?
OPKO Health saw a increase in short interest in the month of June. As of June 29th, there was short interest totalling 73,202,179 shares, an increase of 0.9% from the June 15th total of 73,903,777 shares. Based on an average daily trading volume, of 7,858,911 shares, the short-interest ratio is currently 9.3 days. Currently, 22.5% of the company's shares are short sold. View OPKO Health's Current Options Chain.
Who are some of OPKO Health's key competitors?
Some companies that are related to OPKO Health include Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Genmab A/S (GNMSF), Perrigo (PRGO), Sarepta Therapeutics (SRPT), Beigene (BGNE), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS) and United Therapeutics (UTHR).
Who are OPKO Health's key executives?
OPKO Health's management team includes the folowing people:
- Dr. Philip Frost, Chairman and Chief Exec. Officer (Age 82)
- Dr. Jane H. Hsiao Ph.D., MBA, Vice Chairman and Chief Technical Officer (Age 71)
- Mr. Adam E. Logal, Chief Financial Officer, Chief Accounting Officer, Sr. VP and Treasurer (Age 40)
- Mr. Steven D. Rubin, Exec. VP of Admin. and Director (Age 58)
- Ms. Kate Inman Esq., Deputy Gen. Counsel and Sec. (Age 45)
Has OPKO Health been receiving favorable news coverage?
Media stories about OPK stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. OPKO Health earned a news impact score of 0.20 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 47.78 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are OPKO Health's major shareholders?
OPKO Health's stock is owned by a number of of retail and institutional investors. Top institutional investors include Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (0.31%), RK Asset Management LLC (0.18%), Essex Investment Management Co. LLC (0.05%), Cito Capital Group LLC (0.02%), Amalgamated Bank (0.01%) and North Star Investment Management Corp. (0.01%). Company insiders that own OPKO Health stock include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Opko Health, Inc, Phillip Md Et Al Frost, Richard A Lerner, Robert Scott Fishel and Steven D Rubin. View Institutional Ownership Trends for OPKO Health.
Which major investors are selling OPKO Health stock?
Which major investors are buying OPKO Health stock?
OPK stock was bought by a variety of institutional investors in the last quarter, including RK Asset Management LLC, Cito Capital Group LLC, North Star Investment Management Corp. and Essex Investment Management Co. LLC. Company insiders that have bought OPKO Health stock in the last two years include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Opko Health, Inc, Phillip Md Et Al Frost, Richard A Lerner, Robert Scott Fishel and Steven D Rubin. View Insider Buying and Selling for OPKO Health.
How do I buy shares of OPKO Health?
Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OPKO Health's stock price today?
One share of OPK stock can currently be purchased for approximately $5.89.
How big of a company is OPKO Health?
OPKO Health has a market capitalization of $3.33 billion and generates $1.07 billion in revenue each year. The biotechnology company earns $-308,870,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. OPKO Health employs 6,030 workers across the globe.
How can I contact OPKO Health?
OPKO Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected]
MarketBeat Community Rating for OPKO Health (NASDAQ OPK)
MarketBeat's community ratings are surveys of what our community members think about OPKO Health and other stocks. Vote "Outperform" if you believe OPK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPK will underperform the S&P 500 over the long term. You may vote once every thirty days.
